Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Next Science (NXS), has been granted its first acne-related patent
- This patent allows the company to apply its unique Xbio technology to treating chronic acne
- Xbio is a non-toxic technology that attacks biofilm bacteria which can affect every organ, including the skin
- Next Science is up 6.82 per cent and shares are trading for $1.80 each
Pioneer biotechnology company Next Science (NXS), has been granted its first acne-related patent.
The U.S. Patent Office granted Next Science Patent No. 10,477,860 for “High Osmolarity Antimicrobial Composition Containing One or More Organics Solvents.”
This provides patent coverage for the company to apply its unique Xbio technology in its acne gel and acne creams.
Next Science’s aim is to eradicate biofilm bacteria and planktonic bacteria with a non-toxic technology that disrupts the biofilm’s extracellular polymeric substance (EPS) matrix – this technology is Xbio.
The Xbio technology attacks the biofilm structures by breaking the strong metallic bonds that hold the EPS together. This exposes the biofilm’s bacteria and makes them more vulnerable to eradication.
Biofilms are highly resistant forms of bacterial infections and have a major negative impact on the healthcare economy. Next Science reported it costs the U.S. $94 billion (A$135 billion) annually.
According to the US National Institutes of Health, chronic biofilm infections can affect every organ system in the human body, including skin.
Chronic acne is a biofilm-based infection. By applying Next Science’s unique biofilm to treat acne, the company has been able to create formulas that break up the biofilm and restore the natural biome of the skin.
The patent gives Next Science a unique platform to commercialise and licence acne treatments, as well as other technologies in its portfolio.
Next Science is up 6.82 per cent and shares are trading for $1.80 each at market close.
